Income Statement
ANNOVIS BIO, INC.
ANVS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - |
|
Operating Expenses
|
29.70 | 26.69 | 45.04 | 25.51 | 14.54 | 6.64 |
|
Research & Development
|
25.22 | 20.00 | 38.79 | 16.52 | 8.48 | 3.05 |
|
Selling, General & Administrative
|
4.48 | 6.70 | 6.24 | 9.00 | 6.06 | 3.59 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-29.70 | -26.69 | -45.04 | -25.51 | -14.54 | -6.64 |
|
Non-Operating Income
|
0.84 | 2.10 | -11.17 | 0.18 | 0.05 | 1.18 |
|
Interest Income
|
0.70 | 0.33 | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - |
|
Income Before Tax
|
- | - | -56.20 | -25.33 | -14.49 | -5.46 |
|
Income Tax Expense
|
- | - | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-28.85 | -24.59 | -56.20 | -25.33 | -14.49 | -5.46 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-29.70 | -26.69 | -45.04 | -25.51 | -14.54 | -6.64 |
|
Earnings Per Share (Basic)
|
-1.40 | -2.02 | -6.23 | -3.10 | -1.90 | - |
|
Diluted EPS
|
-1.40 | -2.31 | -6.23 | -3.10 | -1.90 | - |
|
Weighted Average Shares
|
20.55 | 12.18 | 9.02 | 8.16 | 7.63 | - |
|
Diluted Weighted Avg Shares
|
20.55 | 12.24 | 9.02 | 8.16 | 7.63 | - |
|
Comprehensive Income
|
- | - | - | - | - | - |